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translation methodology included two forward transla-
tions by native speakers in each language, a reconciled
version of the two forwards by a third translator, back-
translation of the reconciled version by a native English
speaker ﬂuent in the target language, and three indepen-
dent reviews by native speaking experts. Retrospective
debrieﬁng interviews were conducted in which 113
patients (20 in Portugal, 20 in Japan, 19 in Brazil, 34 in
Israel, and 20 in Korea) diagnosed with multiple sclero-
sis were asked to read and answer the questionnaire in
Portuguese, Japanese, Hebrew, Russian, or Korean and
then give their opinion on any problems with the trans-
lation or the content of the questionnaire. Statistical
analyses (descriptive statistics and reliability analyses)
were performed on the quantitative data, and the partic-
ipant comments were reviewed. RESULTS: Age range
was 19 to 64 years; there were 75 women and 38 men.
The FAMS performed very well in all target languages.
Cronbach’s alpha coefﬁcients for total FAMS were high
(range = 0.93–0.96), indicating overall scale homogene-
ity comparable to the original English version. Based
upon statistical analyses and comments from patients, no
revisions were necessary for the Portuguese, Japanese,
Russian, and Korean translations. However, two revi-
sions were made to the Hebrew version as a result of data
collected during testing. CONCLUSIONS: Participants
were comfortable with the questionnaire and felt that the
questions addressed issues important to multiple sclero-
sis. The ﬁnal versions of the Portuguese, Japanese,
Hebrew, Russian, and Korean FAMS are linguistically
acceptable and show good psychometric performance,
and are now ready for inclusion in clinical trials and other
research studies to evaluate the quality of life of patients
with multiple sclerosis.
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OBJECTIVE: The complexity of peripheral diabetic 
neuropathy (PDN) and the highly variable effects of indi-
vidual drugs mean that clinicians continue to seek alter-
natives for their patients. The objective of this study was
to evaluate and describe the use of topiramate for PDN
in Canadian clinical practice. METHODS: Retrospective
review of 100 patient charts using physician interview.
Physicians were asked to include the 4 most recent
patients that met the following criteria: 1) diagnosis of
PDN; 2) topiramate started ≥6 months prior to review
date to allow an adequate trial time for drug therapy; 3)
no concomitant gabapentin use. RESULTS: Patient char-
acteristics: 8% Type 1 diabetes, 92% Type 2; mean age
55.4 years; 45% male; 85% Caucasian; 61% with
medical conditions other than diabetes /PDN requiring
drug therapy. Pain distribution: foot/toe 91%, calf 29%,
ﬁnger/hand 28%, thigh 19%. Pain quality: burning 55%,
tingling 47%, pins and needles 30%, aching 23%, sharp
19%, cramping 17%, jabbing 17%, shooting 17%. Top-
iramate therapy: mean duration 14.4 months; mean total
daily dose 136mg. 98% were current users. Patients had
PDN for 21.5 months on average prior to starting topi-
ramate therapy. Topiramate was used as monotherapy in
79%. In 59% topiramate was the ﬁrst-line drug. 24%
experienced topiramate-related adverse effects (AEs);
most common: dizziness 29%, somnolence 21%, nausea
17%, and numbness 13%. Actions taken for AEs: none
(71%), dose reduction (17%), slower titration (13%),
treatment with another drug (4%). According to physi-
cian assessment, 64% (95%CI 46, 82) were “very much
improved” or “much improved” for pain, 49% (95%CI
30, 68) for physical activity, and 51% (95%CI 33, 70)
for sleep. CONCLUSIONS: Under conditions of routine
clinical care, topiramate was effective in relieving pain
and improving physical activity and sleep in patients with
PDN. Most patients tolerated the drug long-term with no
discontinuation of therapy resulting from AEs.
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OBJECTIVE: Neuropathic pain is difﬁcult to manage and
pharmacotherapy is often unsatisfactory. Patients often
will have tried a large number of drugs in an effort to ﬁnd
relief. This study evaluated the effectiveness and safety of
topiramate in patients with peripheral diabetic neuropa-
thy (PDN) who have previously tried other anticonvul-
sants. METHODS: Retrospective review of 100 patient
charts using physician interview. Physicians were asked to
include the 4 most recent patients that met the following
criteria: 1) diagnosis of PDN; 2) topiramate started ≥6
months prior to review date to allow an adequate trial
time for drug therapy; 3) no concomitant gabapentin use.
A subgroup of 28 patients that had failed other anticon-
vulsants prior to topiramate was analyzed. RESULTS:
Patient characteristics: 14% Type 1 diabetes, 86% Type
2; mean age 64.9 years; 54% males; 93% Caucasian.
Most commonly affected areas: foot/toe (82%), calf
(36%), ﬁnger/hand (32%), thigh (21%). Most common
qualities: burning (57%), tingling (50%), aching (46%),
pins and needles (21%). Previous anticonvulsants
included gabapentin (82%), carbamazepine (29%), clon-
azepam (4%), and divalproex (4%). The most common
